Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Swedish Orphan Biovitrum AB (PK) BIOVF

Alternate Symbol(s):  SWOBY

Healthcare Drug Manufacturers - Specialty & Generic
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients... see more

Recent & Breaking News (PINL:BIOVF)

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes

PR Newswire July 15, 2025

Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB

PR Newswire March 2, 2023

Realising opportunities for future growth and financial update: Sobi Capital Markets Day 2020

PR Newswire December 10, 2020

Sobi launch Doptelet® (avatrombopag) in Europe

PR Newswire November 4, 2020

Sobi publishes report for the third quarter 2020

PR Newswire October 22, 2020

Sobi announces topline phase 3 data of avatrombopag for the treatment of Chemotherapy-Induced Thrombocytopenia

PR Newswire October 9, 2020

Invitation - Presentation of Sobi's Q3 2020 results

PR Newswire October 7, 2020

Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout

PR Newswire September 30, 2020

Sobi and Sanofi Donate up to 500 Million Additional IUs of Clotting Factor to WFH Humanitarian Aid Program

PR Newswire June 14, 2020

Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine

PR Newswire May 7, 2020

Invitation - Presentation of Sobi's Q1 2020 Results

PR Newswire April 22, 2020

Sobi(TM) Affiliate Florio GmbH, Launches a New Digital Platform Aiming to Improve the Lives of People with Haemophilia

PR Newswire April 22, 2020

Sobi Offers Advance Voting at the 2020 Annual General Meeting

PR Newswire April 20, 2020

New Research Uncovers the Toll Rare Diseases Take on Relationships

PR Newswire February 28, 2020

Sobi Publishes Report for the Fourth Quarter and Full-year 2019

PR Newswire February 13, 2020

Invitation - Presentation of Sobi's Q4/FY 2019 Results

PR Newswire February 4, 2020

FDA Grants Avatrombopag Orphan Drug Designation for the Treatment of Chemotherapy-induced Thrombocytopenia

PR Newswire December 21, 2019

Data to be Highlighted at the American Society of Hematology 2019 Annual Meeting

PR Newswire December 5, 2019

Sobi Publishes Report for Third Quarter 2019

PR Newswire October 31, 2019

Invitation - Presentation of Sobi's Q3 2019 Results

PR Newswire October 23, 2019

Podcasts